Last reviewed · How we verify
Oteseconazole (VT-1161)
Oteseconazole (VT-1161) is a Azole antifungal Small molecule drug developed by Mycovia Pharmaceuticals Inc.. It is currently in Phase 3 development for Vulvovaginal candidiasis, Oral candidiasis.
Oteseconazole is a selective inhibitor of fungal lanosterol 14α-demethylase (CYP51) that disrupts ergosterol synthesis in fungal cell membranes.
Oteseconazole is a selective inhibitor of fungal lanosterol 14α-demethylase (CYP51) that disrupts ergosterol synthesis in fungal cell membranes. Used for Vulvovaginal candidiasis, Oral candidiasis.
At a glance
| Generic name | Oteseconazole (VT-1161) |
|---|---|
| Sponsor | Mycovia Pharmaceuticals Inc. |
| Drug class | Azole antifungal |
| Target | Fungal lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the CYP51 enzyme, oteseconazole prevents the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. This leads to accumulation of toxic sterol precursors and membrane destabilization, ultimately causing fungal cell death. The drug is designed to have improved selectivity for fungal CYP51 over human cytochrome P450 enzymes compared to earlier azole antifungals.
Approved indications
- Vulvovaginal candidiasis
- Oral candidiasis
Common side effects
- Headache
- Nausea
- Abdominal pain
- Diarrhea
Key clinical trials
- A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (PHASE3)
- A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (PHASE3)
- Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）
- Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oteseconazole (VT-1161) CI brief — competitive landscape report
- Oteseconazole (VT-1161) updates RSS · CI watch RSS
- Mycovia Pharmaceuticals Inc. portfolio CI
Frequently asked questions about Oteseconazole (VT-1161)
What is Oteseconazole (VT-1161)?
How does Oteseconazole (VT-1161) work?
What is Oteseconazole (VT-1161) used for?
Who makes Oteseconazole (VT-1161)?
What drug class is Oteseconazole (VT-1161) in?
What development phase is Oteseconazole (VT-1161) in?
What are the side effects of Oteseconazole (VT-1161)?
What does Oteseconazole (VT-1161) target?
Related
- Drug class: All Azole antifungal drugs
- Target: All drugs targeting Fungal lanosterol 14α-demethylase (CYP51)
- Manufacturer: Mycovia Pharmaceuticals Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Vulvovaginal candidiasis
- Indication: Drugs for Oral candidiasis
- Compare: Oteseconazole (VT-1161) vs similar drugs
- Pricing: Oteseconazole (VT-1161) cost, discount & access